$RVVTF News

Last published 11mo ago

11mo agoRVVTFRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure StudyGlobeNewswireTORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
11mo agoRVVTFRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure StudyGlobeNewswireTORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics Announces Closing of Second Tranche of Private PlacementGlobeNewswireTORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative
1y agoRVVTFRevive Therapeutics Announces Extension of Proposed Private PlacementGlobeNewswireTORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative
1y agoRVVTFRevive Therapeutics Announces Closing of First Tranche of Private Placement and Debt SettlementGlobeNewswireTORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative
1y agoRVVTFRevive Therapeutics Announces Proposed Private Placement and Debt SettlementGlobeNewswireTORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative
1y agoRVVTFRevive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling OpportunityGlobeNewswireTORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics Advances with Next-Generation Bucillamine DevelopmentGlobeNewswireTORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative
1y agoRVVTFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureGlobeNewswireTORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics Announces Proposed Shares for Debt TransactionGlobeNewswireTORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics to Investigate Bucillamine's Potential in Cancer TreatmentGlobeNewswireTORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoDGNMF RVVTFRevive Therapeutics Announces Acquisition of Molecular Hydrogen ProgramGlobeNewswireTORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics Announces Results of Annual Shareholder MeetingGlobeNewswireTORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoDGNMF RVVTFRevive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen ProgramGlobeNewswireTORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- TORONTO, March 3, 2025 – Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the
1y agoRVVTFRevive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical CountermeasuresGlobeNewswireTORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoRVVTFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureGlobeNewswireTORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
1y agoPHRRF RVVTFRevive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in StrokeGlobeNewswireTORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureGlobeNewswireTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical CountermeasuresGlobeNewswireTORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral InfectionsGlobeNewswireTORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureGlobeNewswireTORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVIDGlobeNewswireTORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic ProductGlobeNewswireTORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDGlobeNewswireTORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductGlobeNewswireTORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
2y agoPHRRF RVVTFRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use DisorderGlobeNewswireTORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDGlobeNewswireTORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDGlobeNewswireTORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Corporate UpdateGlobeNewswireTORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110GlobeNewswireNOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE
2y agoRVVTFRevive Therapeutics Explores the Use of Bucillamine for Long COVIDGlobeNewswireTORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500GlobeNewswireNOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE
2y agoRVVTFRevive Therapeutics Ltd. Announces Offering of Up to $3 MillionGlobeNewswireNOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE
2y agoRVVTFRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaGlobeNewswireTORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineGlobeNewswireTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersGlobeNewswireTORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineGlobeNewswireTORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
2y agoRVVTFRevive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentGlobeNewswireTORONTO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid TestGlobeNewswirePotential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company")
3y agoRVVTFRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureGlobeNewswireTORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentGlobeNewswireTORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Announces Initiation of Novel Bucillamine Formulation DevelopmentGlobeNewswireTORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare AgentsGlobeNewswireTORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19GlobeNewswireTORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19GlobeNewswireTORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19GlobeNewswireTORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19GlobeNewswireTORONTO, May 02, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
3y agoRVVTFRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19GlobeNewswireTORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
3y agoPHRRF RVVTFRevive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla BiotechGlobeNewswirePurchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023
3y agoRVVTFRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use DisorderGlobeNewswireTORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of